Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Imaging Studies and the Development of Multiple Myeloma

This study has been withdrawn prior to enrollment.
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ) Identifier:
First received: April 4, 2012
Last updated: April 19, 2017
Last verified: April 16, 2014


- Multiple myeloma (MM) is a type of malignant blood cancer. It affects the plasma cells, which help produce antibodies and fight infection. MM is nearly always preceded by a pre-malignant state, monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). Currently, it is not possible to predict when someone with MGUS or SMM will develop MM. Also, the disease changes in those early states are not well understood. Researchers want to look at imaging studies of people with MGUS, SMM, and MM. They will study whether the growth of blood vessels can be used to predict disease progression.


- To use imaging studies to evaluate disease progression in multiple myeloma.


- Individuals at least 18 years of age who have MGUS, SMM, or newly diagnosed MM.


  • Participants will be screened with a physical exam and medical history. They will also have blood and urine tests, and provide bone marrow samples.
  • Participants will have positron emission tomography (PET) scans with the new contrast agent [18]F-Fluciclatide. The contrast agent is intended to show patterns of increased vessel growth in the bone marrow.
  • Participants will also have a magnetic resonance imaging (MRI) scan. This scan will be done according to standard procedures.
  • Researchers will compare these scans with blood tests and other clinical information to study disease progression of MGUS, SMM, and MM....

Condition Intervention Phase
Multiple Myeloma
Smoldering Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance
Drug: Fluciclatide
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Primary Purpose: Diagnostic
Official Title: Novel Imaging Modalities to Characterize Angiogenesis in the Bone Marrow Microenvironment in Multiple Myeloma (MM) and Its Precursor Disease

Resource links provided by NLM:

Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • To explore the distribution of 18F-Fluciclatide PET/CT in bone marrow microenvironment in patients with multiple myeloma and its precursor disease (MGUS and SMM) [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Distribution of agent [ Time Frame: 2 years ]

Enrollment: 0
Study Start Date: March 27, 2012
Study Completion Date: April 23, 2014
Primary Completion Date: April 23, 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Fluciclatide
  Show Detailed Description


Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Diagnosis of MGUS, SMM and MM will be made in accordance with the clinical diagnostic criteria set forth by the International Myeloma Working Group. The diagnosis will be confirmed by the following diagnostic tests:

    • serum/urine protein electrophoresis
    • serum/urine immunofixation,
    • light-chain assays,
    • a skeletal survey, or
  • immunohistochemistry analyses of the bone marrow biopsy, or
  • a combination of these at the NIH

Note: Written results from institutions outside of NIH for the above tests will be accepted if available.

  • Age greater than or equal to 18 years.
  • ECOG performance status of 0-2.
  • The patient must be competent to sign an informed consent form.
  • Platelet count = or > 100,000. Subjects must weight <320lbs
  • Creatinine <2.5 times ULN or eGFR>30 ml/min/1.73m(2)


  • A medical history of other malignancy (apart from basal cell carcinoma of the skin or in situ cervical carcinoma; also, for MM patients this does not include MM) except if the patient has been free of symptoms and without active therapy during at least the previous 3 years.
  • Patients with documented metastatic lesions from another type of malignancy will be excluded.
  • Female subject is pregnant or breast-feeding.
  • The subject has known allergy to gadolinium
  • The subject has contraindications to MRI

    • Subjects must weigh <136 kg (weight limit for scanner table).
    • Subjects cannot have pacemakers, cerebral aneurysm clips, shrapnel injury, or other implanted electronic devices or metal not compatible with MRI.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01571726

Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Carl O Landgren, M.D. National Cancer Institute (NCI)
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT01571726     History of Changes
Other Study ID Numbers: 120106
Study First Received: April 4, 2012
Last Updated: April 19, 2017

Keywords provided by National Institutes of Health Clinical Center (CC):
(18)-Fluciclatide PET/CT
Serum M-Protein
Percentage of Plasma Cells in the Bone Marrow
Ratio of Normal/Abnormal Percentage of Plasma Cells in the Bone Marrow
Multiple Myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Monoclonal Gammopathy of Undetermined Significance
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Hypergammaglobulinemia processed this record on April 21, 2017